Author Archives: Natalie Themm
Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
EVŌQ Nano Expands Antimicrobial Medical Device Platform, Demonstrates Efficacy Across Multiple Device Applications
Four Integration Methods Aim to Combat Healthcare-Associated Infections & Improve Device Performance
SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT
SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
Seek Labs Announces Partnership with Cerbrec to Accelerate Diagnostic and Therapeutic Innovation with Graphbook Software
Seek Labs Announces Partnership with Cerbrec
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming CellProfiler
The Future Of Inflammation: The Inflammasome And Beyond
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
